|
MCID: CRV002
|
Cervix Uteri Carcinoma in Situ malady |
|
Sources: 22MalaCards See all sources Export this MalaCard |
MalaCards: Cervix Uteri Carcinoma in Situ, also known as carcinoma in situ of uterine cervix, is related to adenocarcinoma in situ and hepatocellular carcinoma. An important gene associated with Cervix Uteri Carcinoma in Situ is MRFAP1 (Morf4 family associated protein 1), and among its related pathways are Platelet Aggregation Inhibitor Pathway, Pharmacodynamics and Blood Coagulation Signaling Pathways. The drugs carmustine and diethylstilbestrol diphosphate have been mentioned in the context of this disorder. Affiliated tissues include cervix.
|
|
Sources: 6Disease Ontology, 8DISEASES, 43UMLS, 40SNOMED-CT, 19ICD9CM, 24MeSH, 27NCIt See all sources |
Aliases & Descriptions:
|
|
|
|
Sources: 4CenterWatch, 29NIH Clinical Center, 5ClinicalTrials, 43UMLS, 28NDF-RT See all sources |
Approved drugs:Search CenterWatch for cervix uteri carcinoma in situ Drug clinical trials:Search ClinicalTrials for cervix uteri carcinoma in situ Search NIH Clinical Center for cervix uteri carcinoma in situ Search CenterWatch for cervix uteri carcinoma in situ Inferred drug relations via UMLS/NDF-RT:43 28 carmustine, diethylstilbestrol, diethylstilbestrol diphosphate, nilutamide |
|
|
|
Sources: 22MalaCards See all sources |
MalaCards organs/tissues related to cervix uteri carcinoma in situ:22Cervix
|
|
|
|
|
|
Sources: 1BioGPS See all sources |
![]() |
|
Sources: 34PharmGKB, 37R&D Systems See all sources |
Pathways related to cervix uteri carcinoma in situ according to GeneDecks:
|
|
|
|
Sources: 12Gene Ontology See all sources |
